Literature DB >> 21112960

YAP is a candidate oncogene for esophageal squamous cell carcinoma.

Tomoki Muramatsu1, Issei Imoto, Takeshi Matsui, Ken-Ichi Kozaki, Shigeo Haruki, Marius Sudol, Yutaka Shimada, Hitoshi Tsuda, Tatsuyuki Kawano, Johji Inazawa.   

Abstract

Yes-associated protein (YAP), the nuclear effector of the Hippo pathway, is a key regulator of organ size and a candidate human oncogene located at chromosome 11q22. Since we previously reported amplification of 11q22 region in esophageal squamous cell carcinoma (ESCC), in this study we focused on the clinical significance and biological functions of YAP in this tumor. Frequent overexpression of YAP protein was observed in ESCC cells including those with a robust amplicon at position 11q22. Overexpression of the YAP protein was frequently detected in primary tumors of ESCC as well. Patients with YAP-overexpressing tumors had a worse overall rate of survival than those with non-expressing tumors, and YAP positivity was independently associated with a worse outcome in the multivariate analysis. Further analyses in cells in which YAP was either overexpressed or depleted confirmed that cell proliferation was promoted in a YAP isoform-independent but YAP expression level-dependent manner. YAP depletion inhibited cell proliferation mainly in the G(0)-G(1) phase and induced an increase in CDKN1A/p21 transcription but a decrease in BIRC5/survivin transcription. Our results indicate that YAP is a putative oncogene in ESCC and it represents a potential diagnostic and therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112960     DOI: 10.1093/carcin/bgq254

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  115 in total

Review 1.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.

Authors:  Anwesha Dey; Xaralabos Varelas; Kun-Liang Guan
Journal:  Nat Rev Drug Discov       Date:  2020-06-17       Impact factor: 84.694

2.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Authors:  Gilson S Baia; Otavia L Caballero; Brent A Orr; Anita Lal; Janelle S Y Ho; Cynthia Cowdrey; Tarik Tihan; Christian Mawrin; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2012-05-22       Impact factor: 5.852

3.  YAP regulates cell proliferation, migration, and steroidogenesis in adult granulosa cell tumors.

Authors:  David Fu; Xiangmin Lv; Guohua Hua; Chunbo He; Jixin Dong; Subodh M Lele; David Wan-Cheng Li; Qiongli Zhai; John S Davis; Cheng Wang
Journal:  Endocr Relat Cancer       Date:  2014-03-04       Impact factor: 5.678

4.  YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.

Authors:  Bo Tu; Jun Yao; Sammy Ferri-Borgogno; Jun Zhao; Shujuan Chen; Qiuyun Wang; Liang Yan; Xin Zhou; Cihui Zhu; Seungmin Bang; Qing Chang; Christopher A Bristow; Ya'an Kang; Hongwu Zheng; Huamin Wang; Jason B Fleming; Michael Kim; Timothy P Heffernan; Giulio F Draetta; Duojia Pan; Anirban Maitra; Wantong Yao; Sonal Gupta; Haoqiang Ying
Journal:  JCI Insight       Date:  2019-11-01

5.  Downregulation of YAP inhibits proliferation and induces apoptosis in Eca-109 cells.

Authors:  Mu Cui; Zhen Li
Journal:  Exp Ther Med       Date:  2017-11-10       Impact factor: 2.447

6.  Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.

Authors:  Avnish Kapoor; Wantong Yao; Haoqiang Ying; Sujun Hua; Alison Liewen; Qiuyun Wang; Yi Zhong; Chang-Jiun Wu; Anguraj Sadanandam; Baoli Hu; Qing Chang; Gerald C Chu; Ramsey Al-Khalil; Shan Jiang; Hongai Xia; Eliot Fletcher-Sananikone; Carol Lim; Gillian I Horwitz; Andrea Viale; Piergiorgio Pettazzoni; Nora Sanchez; Huamin Wang; Alexei Protopopov; Jianhua Zhang; Timothy Heffernan; Randy L Johnson; Lynda Chin; Y Alan Wang; Giulio Draetta; Ronald A DePinho
Journal:  Cell       Date:  2014-06-19       Impact factor: 41.582

7.  KRAS and YAP1 converge to regulate EMT and tumor survival.

Authors:  Diane D Shao; Wen Xue; Elsa B Krall; Arjun Bhutkar; Federica Piccioni; Xiaoxing Wang; Anna C Schinzel; Sabina Sood; Joseph Rosenbluh; Jong W Kim; Yaara Zwang; Thomas M Roberts; David E Root; Tyler Jacks; William C Hahn
Journal:  Cell       Date:  2014-06-19       Impact factor: 41.582

8.  VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex.

Authors:  Wenjing Zhang; Yijun Gao; Peixue Li; Zhubing Shi; Tong Guo; Fei Li; Xiangkun Han; Yan Feng; Chao Zheng; Zuoyun Wang; Fuming Li; Haiquan Chen; Zhaocai Zhou; Lei Zhang; Hongbin Ji
Journal:  Cell Res       Date:  2014-01-24       Impact factor: 25.617

9.  BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.

Authors:  Kenta Moriyama; Toshiyuki Hori
Journal:  Int J Hematol       Date:  2019-08-19       Impact factor: 2.490

10.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.